Axsome Therapeutics, Inc. (AXSM)
Summary
AXSM Chart
People also search for
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.
Why Axsome Stock Has Doubled In Nine Months
In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more. To get it in your inbox, subscribe here.
Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Axsome Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 56 | $5,992.21 | $13,051.99 | $7,059.78 | 117.82% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 60 | $6,229.32 | $14,055.3 | $7,825.98 | 125.63% |
 Farallon Capital Farallon Capital Management LLC | 4,000 | $287,440 | $934,761.2 | $647,321.2 | 225.2% |
| BG Bart Gancher Intech Investment Management LLC | 9,919 | $1.03M | $2.32M | $1.3M | 125.95% |
 Bridgewater Associates LP Bridgewater Associates LP | 56,951 | $10.27M | $13.31M | $3.04M | 29.6% |
Axsome Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Graig Suvannavejh Mizuho | 125.15 | $28,146.29 | $28,784.1 | $637.81 | 2.27% |
Axsome Therapeutics, Inc. (AXSM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Axsome Therapeutics, Inc. ever had a stock split?
Axsome Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Herriot Tabuteau CEO | NASDAQ (NMS) Exchange | 05464T104 CUSIP |
| US Country | 925 Employees | - Last Dividend | - Last Split | 19 Nov 2015 IPO Date |
Overview
Axsome Therapeutics, Inc. is a forward-thinking biopharmaceutical entity dedicated to the innovation of novel treatments geared towards addressing the complexities of central nervous system (CNS) disorders. Rooted in the quest to improve patient care within the United States, Axsome stands out for its dynamic approach towards tackling conditions such as major depressive disorder, narcolepsy, obstructive sleep apnea, Alzheimer's disease agitation, and more. The foundation of the company's operations, established in 2012 and headquartered in New York, New York, underscores a commitment to pushing the boundaries of medical science, particularly in the CNS domain. Through its research collaboration with Duke University focused on smoking cessation, Axsome exemplifies its dedication to pioneering efforts in enhancing therapeutic outcomes.
Products and Services
- Auvelity (dextromethorphan-bupropion): An innovative N-methyl-D-aspartate receptor antagonist showcasing multimodal activity, specifically indicated for the treatment of major depressive disorder, highlighting Axsome's focus on addressing mental health challenges with novel approaches.
- Sunosi (solriamfetol): A targeted medication addressing excessive daytime sleepiness in patients battling narcolepsy or obstructive sleep apnea, underlining the company's dedication to improving quality of life for individuals with sleep disorders.
Under Development:
- AXS-05: Currently in Phase III clinical trial for Alzheimer's disease agitation, showcasing Axsome's deep dive into neurodegenerative disease management. Additionally, it demonstrates versatility with its completion of Phase II clinical trial for smoking cessation.
- AXS-07: An investigational medicine that has successfully completed Phase III trials, crafted for the acute treatment of migraine, providing a glimpse into Axsome's commitment to tackling severe headache disorders.
- AXS-12: In Phase III trial to treat narcolepsy, positioning Axsome at the forefront of addressing sleep disorders with cutting-edge solutions.
- AXS-14: Having completed Phase III trial for the treatment of fibromyalgia, this selective and potent norepinephrine reuptake inhibitor represents Axsome's venture into pain management and other potential conditions.
- Solriamfetol: Beyond its approved use, it is under investigation in a Phase 2 trial for addressing attention-deficit/hyperactivity disorder. Additionally, its exploration extends to major depressive, binge eating, and shift work disorders, showing Axsome's holistic approach to CNS conditions.
